prostate cancer
Conditions
Interventions
Gold Standard:Needle biopsy of prostate tumor guided by color doppler ultrasound
Index test:DNA mutation analysis,DNA methylation analysis,PSA
Sponsors
ShenZhen HaploX Biotechnology Co., LTD
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Be able to provide written informed consent and understand and agree to comply with the study requirements; 2. Males older than 18 years of age; 3. Inclusion criteria for prostate cancer patients: Patients diagnosed with prostate cancer by needle biopsy did not receive treatment including castration, antiandrology, radiotherapy and chemotherapy before inclusion; 4. Inclusion criteria for non-prostate cancer patients: patients with benign prostate disease who were excluded from prostate cancer by systematic needle biopsy; 5. Inclusion criteria for healthy men: men without clinical indications of prostate disease; 6. Early screening criteria: patients with PSA>=4ng/ml.
Exclusion criteria
Exclusion criteria: 1. Previous castration and/or anti-male drug therapy, chemotherapy, radiotherapy, etc.; Patients with a history of other malignant tumors; 2. The patient has received a blood transfusion within 3 months or has had a bone marrow transplant in the past; 3. The patient has other major diseases in the recent 3 months and has received corresponding treatment; 4. Alcohol or drug abuse; 5. Other circumstances that the researcher considers may affect the results of the experiment or be unethical.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DNA mutation analysis;DNA methylation analysis;Prostate specific antigen; | — |
Countries
China
Contacts
Public ContactZhang Xiaoni
ShenZhen HaploX Biotechnology Co., LTD
Outcome results
None listed